Low-Dose Thalidomide Plus Monthly High-Dose Oral Dexamethasone (Thali-Dexa): Results, Prognostic Factors and Side Effects in Eight Patients Previously Treated with Multiple Myeloma

Journal of Experimental and Clinical Cancer Research

Volumn 22, Issue 4 SUPPL., 2003, Pages 129-133

  Bernardeschi, Paolo ^a   Dentico, P ^a   Rossi, S ^a   Fiorentini, G ^a   Giustarini, G ^a   Turano, E ^a  

^a SAN GIUSEPPE HOSPITAL   (Italy)

Author keywords

Chemotherapy; Dexamethasone; Myeloma; Thalidomide

Indexed keywords

DEXAMETHASONE; THALI DEXA; THALIDOMIDE;

ADULT; AGED; BRAIN ISCHEMIA; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DOSE RESPONSE; DRUG DOSE REGIMEN; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; KIDNEY FAILURE; MALE; MULTIPLE MYELOMA; NEUROPATHY; PANCYTOPENIA; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; SOFT TISSUE TUMOR; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD SEDIMENTATION; DEXAMETHASONE; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; SALVAGE THERAPY; SURVIVAL ANALYSIS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 1842583277     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (14)

1. Singhal S., Mehta J., Desikan R., Ayers D., Roberson P., Eddlemon P., Munshi N., Anaissie E., Wilson C., Dhodapkar M., Zeldis J., Barlogie B., Siegel D., Crowley J.: Antitumor Activity of Thalidomide in Refractory Multiple Myeloma. N. Engl. J. Med. 341:1565-1571, 1999.
2. Yakoub-Agha I., Attal M., Dumontet C., Delannoy V., Moreau P., Berthou C., Lamy T., Grosbois B., Dauriac C., Dorvaux V., Bay J.O., Monconduit M., Harousseau J.L., Duguet C., Duhamel A., Facon T.: Thalidomide in patients with advanced multiple myeloma: a study of 83 patients. Report of the Intergroupe Francophone du Myélome (IFM). Hematol. J. 3: 185-92, 2002.
3. Osman K., Comenzo R., Rajkumar S.: V Deep Venous Thrombosis and Thalidomide Therapy for Multiple Myeloma. N.E.J.M. 344:1951-1952 4, 2001.
4. Raijkumar S.V., Gertz M.A., Witzig T.E.: Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma. N. Engl. J. Med. 343:972-73, 2000.
5. Morgan A.E., Smith W.K., Levenson J.L.: Reversible Dementia Due to Thalidomide Therapy for Multiple Myeloma. N. Engl. J. Med. 348:1821-1822, 2003.
6. Weber D., Rankin K., Delasalle K., Alexanian R.: Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J. Clin. Oncol. 21:16-9, 2003.
7. Palumbo A., Giaccone I., Bertola A., Pregno P., Bringhen S., Rus C., Triolo S., Gallo E., Pileri A., Boccadoro M.: Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 86:399-403, 2002.
8. Osman K., Comenzo R., Raijkumar S.V.: Deep venous thrombosis and thalidomide therapy for multiple myeloma. N. Engl. J. Med. 344:1951-1952, 2001.
9. Gachon J., Grob J.J., Richard M.A.: Thrombotic accidents induced by thalidomide: two cases. Rev. Med. Interne. 23:724-7, 2002.
10. Weber D., Rankin K., Gavino M., Delasalle K., Alexanian R.: Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J. Clin. Oncol. 21:16-9, 2003.
11. Flageul B., Wallach D., Cavelier-Balloy B., Bechelez H., Carsuzaaa F., Dubertret L.: Thalidomide and thrombosis. Ann. Dermatol. Venereol. 127:171-174, 2000.
12. Alexandrakis M.G., Passam F.H., Ganotakis E.S., Sfiridaki K., Xilouri I., Perisinakis K., Kyriacou D.S.: The clinical and prognostic significance of erythrocyte sedimentation rate (ESR), serum interleukin-2 (IL-2) and acute phase protein levels in multiple myeloma. Clin. Lab. Haematol. 25:41, 2003.
13. Cesana C., Klersy C., Barbarano L., Nosari A.M, Grugnola M., Pungolino E., Gargantini L., Granata S., Valentini M., Morra E.: Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smouldering multiple myeloma. J. Clin. Oncol. 20 (6):1625-34, 2002.
14. E. Galiè, A. Pierangeli, M. Maschio, A. Pace, A. Vidiri, M. Carosi, B. Jandolo,: Demyelinating Disease in Monoclonal Gammopathy. J. Exp. Clin. Cancer Res., 22,337-339, 2003.